OptimizeRx Corp.

Total Valuation

OptimizeRx Corp. carries a market capitalization of 124.51M, placing it among publicly traded companies globally. Its enterprise value stands at 120.53M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

OptimizeRx Corp. currently has 18.77M shares outstanding.

Valuation Ratios

OptimizeRx Corp. trades at a trailing price-to-earnings ratio of 17.11. The price-to-sales ratio is 1.09, and the price-to-book ratio stands at -1.47.

Enterprise Valuation

On an enterprise value basis, OptimizeRx Corp. trades at an EV/EBITDA multiple of 6.39 and an EV/FCF ratio of 6.66. The EV/Sales ratio of 1.12 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.27 provides insight into valuation relative to core operating earnings.

Financial Position

OptimizeRx Corp. maintains a current ratio of 5.37, meaning it holds 5.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.30, indicating elevated leverage, while an interest coverage ratio of 3.66 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, OptimizeRx Corp. has paid 2.75M in income taxes, reflecting an effective tax rate of 28.71.

Stock Price Statistics

OptimizeRx Corp.'s stock has declined approximately -48.48602% over the past 52 weeks. The 50-day moving average sits at 5.53, while the 200-day moving average is 10.33.

Income Statement

Over the trailing twelve months, OptimizeRx Corp. generated 107.35M in revenue and converted that into 6.84M in net income, yielding earnings per share of 0.36. EBITDA reached 18.87M, while operating income came in at 14.57M.

Balance Sheet

OptimizeRx Corp. holds 20.17M in cash and equivalents against 23.72M in total debt, resulting in a net debt position of 3.17M. Total book value stands at -79.71M, with working capital of 45.71M providing operational flexibility.

Cash Flow

OptimizeRx Corp. produced 14.38M in operating cash flow over the past twelve months. After subtracting -52,000.00 in capital expenditures, free cash flow totaled 14.33M - equivalent to 0.77 per share.

Margins

OptimizeRx Corp. operates with a gross margin of 70.04, reflecting its pricing power and cost economics. The operating margin of 13.57 and net profit margin of 6.37 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

OptimizeRx Corp.'s most recent stock split took place on May 14, 2018 with a 3:1 split ratio.

Scores

OptimizeRx Corp. posts an Altman Z-Score of 3.61, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.